文献速递药物不良反应与药物警戒治疗药物监测与药物基因组学肝肾功能剂量调整

培美曲塞相关毒性的机制、管理与预防

Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.
PubMed 文献 · Drug Saf · 2021-11-06

培美曲塞是肺癌治疗基石药物,但部分患者出现剂量限制性或治疗限制性毒性。药代动力学可预测毒性(尤其中性粒细胞减少)。标准维生素补充与地塞米松可降低血液学毒性和皮肤反应,高风险者可用G-CSF预防,高剂量亚叶酸可缓解严重毒性。

要点

  • 培美曲塞药代动力学可预测毒性风险,尤其中性粒细胞减少。
  • 标准维生素补充联合地塞米松可显著降低血液学毒性与皮肤反应。
  • 高剂量亚叶酸可缓解严重培美曲塞毒性,TDM等策略尚待临床验证。

核心结论

  • 培美曲塞药代动力学可作为毒性发生的预后因素,尤其针对中性粒细胞减少。
  • 标准维生素补充与地塞米松已显著降低血液学毒性和皮肤反应发生率。
  • 高剂量亚叶酸可缓解严重培美曲塞诱导的毒性。

研究设计与样本

  • 综述,总结培美曲塞相关毒性的机制、管理与预防策略。

主要发现

  • 培美曲塞可导致黏膜炎、皮肤问题、乏力、肾毒性和中性粒细胞减少等剂量限制性或治疗限制性毒性。
  • 多项研究证实培美曲塞药代动力学可预测毒性发展,尤其对中性粒细胞减少。
  • 标准维生素补充和地塞米松引入后,血液学毒性和皮肤反应发生率大幅下降。
  • 高风险患者可使用粒细胞集落刺激因子预防严重血液学毒性。
  • 高剂量亚叶酸可解决严重培美曲塞诱导的毒性。

关键数值与推荐

  • 标准维生素补充联合地塞米松可显著降低血液学毒性和皮肤反应发生率。
  • 高风险毒性患者可使用粒细胞集落刺激因子预防严重血液学毒性。
  • 高剂量亚叶酸可用于解决严重培美曲塞诱导的毒性。

临床怎么用

  • 临床应常规给予维生素补充和地塞米松以预防培美曲塞相关毒性。
  • 对高毒性风险患者可考虑使用粒细胞集落刺激因子预防严重血液学毒性。
  • 严重培美曲塞毒性可尝试高剂量亚叶酸解救。

局限性

  • 亚叶酸标准用法、血液透析、胸苷、次黄嘌呤、葡萄糖苷酶及治疗药物监测等策略尚需临床评估后方可实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pemetrexed is a cytostatic antifolate drug and a cornerstone in the treatment of lung cancer. Although generally well tolerated, a substantial part of the patient population experiences dose-limiting or even treatment-limiting toxicities. These include mucositis, skin problems, fatigue, renal toxicity, and neutropenia. Several studies confirmed that pemetrexed pharmacokinetics can serve as a prognostic factor for the development of toxicity, especially for neutropenia. Preventing and managing toxicity of pemetrexed can help to ensure durable treatment. Several evidence-based strategies are already implemented in clinical care. With the introduction of standard vitamin supplementation and dexamethasone, the incidence of hematological toxicity and skin reactions substantially decreased. In the case of high risk for toxicity, granulocyte colony-stimulating factor can be used to prevent severe hematological toxicity. Moreover, high-dose folinic acid can resolve severe pemetrexed-induced toxicity. There are several experimental options to prevent or manage pemetrexed-related toxicity, such as the use of standard folinic acid, hemodialysis, antidotes such as thymidine, hypoxanthine, and glucarpidase, and the use of therapeutic drug monitoring. These strategies still need clinical evaluation before implementation, but could enable treatment with pemetrexed for patients who are at risk for toxicity, such as in renal impairment.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. de Rouw N, Piet B, Derijks HJ, et al. Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. Drug Saf. 2021. PMID: 34741752. doi:10.1007/s40264-021-01135-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。